0.00Open9.95Pre Close0 Volume2 Open Interest10.00Strike Price0.00Turnover0.00%IV14.07%PremiumDec 20, 2024Expiry Date7.49Intrinsic Value100Multiplier23DDays to Expiry2.46Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.41Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MediWound Stock Discussion
·3 mins ago
Mediwound Announces U.S. Food and Drug Administration Approval of Nexobrid® for the Treatment of Pediatric Patients With Severe Thermal Burns
No comment yet